**Patient Discharge Summary**

**Patient Information:**

* Name: John Doe
* Date of Birth: March 12, 1975
* Date of Admission: March 15, 2023
* Date of Discharge: March 25, 2023
* Chief Complaint: Fatigue, increased thirst and urination

**Medical History:**

John Doe, a 48-year-old male, was admitted to the endocrinology unit on March 15, 2023, with complaints of fatigue, increased thirst, and urination. He had a medical history of hypertension, hyperlipidemia, and obesity. He was a non-smoker and did not have a significant family history of diabetes.

**Admission and Work-Up:**

Upon admission, John's fasting plasma glucose (FPG) level was 240 mg/dL, and his glycosylated hemoglobin (HbA1C) was 9.2%. He underwent oral glucose tolerance testing (OGTT), which confirmed the diagnosis of type 2 diabetes. His random glucose value was 220 mg/dL. He was also found to have mild hypertension and hyperlipidemia.

**Diagnosis and Treatment:**

John was diagnosed with type 2 diabetes and was started on a treatment regimen consisting of:

* Metformin 500 mg twice daily
* Insulin glargine 10 units at bedtime
* Insulin aspart 10 units before meals
* Metformin 500 mg three times daily
* Lifestyle modifications: diet, exercise, and patient education

John was educated on the causes of diabetes, symptoms and signs of hypoglycemia and hyperglycemia, and diabetic complications. He was also instructed on adjusting insulin doses based on blood glucose levels and carbohydrate intake.

**Dietary Recommendations:**

John was advised to follow a personalized diet plan, focusing on whole foods and high-quality carbohydrates, accommodating his requirements posed by comorbid conditions. He was instructed to consume 150-200 grams of carbohydrates per meal.

**Physical Activity:**

John was recommended to engage in at least 150 minutes of moderate-intensity aerobic exercise per week, with adjustments for hypoglycemia risk. He was also advised to incorporate resistance exercise into his routine.

**Weight Loss Therapy:**

John was prescribed semaglutide 2.4 mg subcutaneously once weekly for weight loss.

**Complications and Monitoring:**

John was screened for diabetic complications, including foot and funduscopic examinations, urine testing for albuminuria, and measurement of serum creatinine and lipid profile. He was also vaccinated against Streptococcus pneumoniae, influenza virus, hepatitis B, varicella, and SARS-CoV-2.

**Discharge Instructions:**

John was discharged from the hospital on March 25, 2023, with the following instructions:

* Continue metformin 500 mg twice daily and insulin glargine 10 units at bedtime
* Adjust insulin doses based on blood glucose levels and carbohydrate intake
* Engage in regular physical activity, including 150 minutes of moderate-intensity aerobic exercise per week
* Monitor blood glucose levels regularly and report any changes to his healthcare provider
* Attend follow-up appointments with his healthcare provider every 3-4 months

**Next Steps:**

John will follow up with his healthcare provider in 3 months for a review of his blood glucose control and any necessary adjustments to his treatment regimen. He will also be referred to a registered dietitian for further dietary counseling and a podiatrist for regular foot care.

**Final Diagnosis:**

John Doe was diagnosed with type 2 diabetes and was treated with a combination of medication and lifestyle modifications. He was discharged from the hospital with instructions for ongoing management and follow-up.